3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Brain Neoplasms
4
Radiation Injuries
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neuroendocrine Tumors
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, B-Cell
1
Lymphoma
1
Liver Neoplasms
1
Liver Diseases
1
Glioma
1
Fibrosis
1
Fatigue
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Carcinoma, Hepatocellular
1
Cancer Related Cognitive Difficulties
1
Breast Neoplasms
1
Interventions
Bevacizumab
47
lenvatinib
36
atezolizumab
36
durvalumab
28
tremelimumab
23
sintilimab
19
Nivolumab
18
pembrolizumab
14
Radiosurgery
13
tislelizumab
11
Specimen Handling
10
Ipilimumab
10
camrelizumab
8
apatinib
8
Oxaliplatin
8
Immune Checkpoint Inhibitors
8
Fluorouracil
8
Cyclophosphamide
8
Blood Specimen Collection
8
regorafenib
7
cabozantinib
7
fludarabine
6
Sorafenib
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
donafenib
5
Surgical Procedures, Operative
5
Injections
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Hepatocellular
×
Neuropsychological Tests
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled